Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938587 · ClinicalTrials.gov registry record · Phase 2
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00938587 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 86 participants.
The verdict
NCT00938587, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. Lastly, this study will measure the PK (amount of drug in the blood) of methotrexate while patients may be taking PF-04171327.
Interventions
- DRUG Prednisone 5 mg
- DRUG PF-04171327 25 mg
- DRUG PF-04171327 10 mg
- OTHER Prednisone Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2009-10-07 |
| Est. Completion | 2010-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938587
The ClinicalTrials.gov registry entry for NCT00938587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone 5 mg is the first listed.
NCT00938587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938587 about?
NCT00938587 is a clinical study titled "A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis". This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rhe...
What is the current status of trial NCT00938587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2009-10-07. Estimated completion is 2010-07-29.
What interventions are being tested in trial NCT00938587?
The interventions under investigation include: Prednisone 5 mg (DRUG), PF-04171327 25 mg (DRUG), PF-04171327 10 mg (DRUG), Prednisone Placebo (OTHER).
Who is sponsoring clinical trial NCT00938587?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.